Cargando…

The complexity of sunitinib dosing in renal cell cancer patients

Detalles Bibliográficos
Autores principales:	Desar, Ingrid M.E., Mulder, Sasja F., Mulders, Peter F.A., van Herpen, Carla M.L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2012
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708252/ https://www.ncbi.nlm.nih.gov/pubmed/26816709 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.05.01

Ejemplares similares

Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study
por: Mulder, Sasja F, et al.
Publicado: (2014)

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour
por: Westerdijk, Kim, et al.
Publicado: (2020)

Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer
por: Krens, Stefanie D., et al.
Publicado: (2021)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial
por: Porta, Camillo, et al.
Publicado: (2012)

Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study
por: Desar, I.M.E., et al.
Publicado: (2011)

Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials
por: Ganapathi, Ram N, et al.
Publicado: (2011)

What a Clinician Should Know About a Renal Replacement Membrane?
por: Honore, Patrick M., et al.
Publicado: (2018)

Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib
por: Beltran, Himisha, et al.
Publicado: (2014)

Who Has Therapy-Related AML?
por: Gale, Robert Peter, et al.
Publicado: (2017)

Immunological consequences of strain variation within the Mycobacterium tuberculosis complex
por: Tientcheu, Leopold D., et al.
Publicado: (2017)

LNKs-RVEs complex ticks in the circadian gating of plant temperature stress responses
por: Xu, Xiaodong, et al.
Publicado: (2023)

EDS1 modules as two-tiered receptor complexes for TIR-catalyzed signaling molecules to activate plant immunity
por: Li, Jia, et al.
Publicado: (2022)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study
por: Zuidema, Sander, et al.
Publicado: (2019)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC
por: Oosterwijk-Wakka, Jeannette C., et al.
Publicado: (2015)

Futility versus utility of marrow assessment in initial Ewing sarcoma staging workup
por: Anderson, Peter M
Publicado: (2015)

Opioid dose regimen shapes mesolimbic adaptations
por: Cahill, Catherine M.
Publicado: (2020)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
por: Huillard, O, et al.
Publicado: (2013)

A promiscuous interaction of SARS-CoV-2 with bacterial products
por: Carissimo, Guillaume, et al.
Publicado: (2020)

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2023)

The Hexadehydro-Diels–Alder Reaction: A New Chapter in Aryne Chemistry
por: Holden (née Hall), Catherine, et al.
Publicado: (2014)

Soluble pattern recognition molecules: Guardians and regulators of homeostasis at airway mucosal surfaces
por: Smole, Ursula, et al.
Publicado: (2020)

ILC1: Development, maturation, and transcriptional regulation
por: Taggenbrock, Renske L.R.E., et al.
Publicado: (2022)

All the small things: How virus‐like particles and liposomes modulate allergic immune responses
por: Kratzer, Bernhard, et al.
Publicado: (2019)

Combination of sunitinib and (177)Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer
por: Oosterwijk-Wakka, Jeannette C., et al.
Publicado: (2022)

Predicting the next move: tracking the complexity of lung cancer evolution and metastasis
por: Lorenz, Carina, et al.
Publicado: (2023)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

‘Nur'turing tumor T cell tolerance and exhaustion: novel function for Nuclear Receptor Nur77 in immunity
por: Lith, Sanne C., et al.
Publicado: (2020)

Identification of biomarkers in pazopanib treated patients with renal cell carcinoma
por: Pick, Amy M., et al.
Publicado: (2013)

What gets turned on in the rhizosphere?
por: Van Dillewijn, Pieter
Publicado: (2008)

Macrophages assemble! But do they need IL‐4R during schistosomiasis?
por: Rückerl, Dominik, et al.
Publicado: (2019)

Revising immune cell coordination: Origins and importance of single‐cell variation
por: Van Eyndhoven, Laura C., et al.
Publicado: (2022)

Tracing the evolution of tissue identity with microRNAs
por: De Mulder, Katrien, et al.
Publicado: (2010)

The role of IL‐23 receptor signaling in inflammation‐mediated erosive autoimmune arthritis and bone remodeling
por: Razawy, Wida, et al.
Publicado: (2018)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kp75ebsf6e3sl1dcpapv4v9ctg